Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 with Irinotecan and Cetuximab in Metastatic CRC
NCT00845039Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2009
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Started May 2009; status: terminated.
02
Drugs
cixutumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00845039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00845039.